Valuation: 3SBio Inc.

Capitalization 61.66B 67.47B 8.6B 7.4B 6.89B 6.42B 11.8B 739B 13.19B 83.46B 31.57B 346B 32.24B 31.57B 1,280B P/E ratio 2025 *
11.1x
P/E ratio 2026 * 21.8x
Enterprise value 60B 65.66B 8.36B 7.2B 6.7B 6.25B 11.48B 719B 12.84B 81.22B 30.72B 336B 31.37B 30.73B 1,245B EV / Sales 2025 *
3.99x
EV / Sales 2026 * 5.02x
Free-Float
72.15%
Yield 2025 *
0.9%
Yield 2026 * 1.49%
More valuation ratios * Estimated data
Dynamic Chart
1 day+1.42%
1 week+16.50%
Current month+20.93%
1 month+22.75%
3 months+122.40%
6 months+396.53%
Current year+370.39%
More quotes
1 week 23.7
Extreme 23.7
29.1
1 month 20.1
Extreme 20.1
29.1
Current year 5.6
Extreme 5.6
29.1
1 year 5.47
Extreme 5.47
29.1
3 years 4.86
Extreme 4.86
29.1
5 years 4.72
Extreme 4.72
29.1
10 years 4.72
Extreme 4.72
29.1
More quotes
Manager TitleAgeSince
Chief Executive Officer 62 01/01/2006
Director of Finance/CFO - 03/07/2023
Corporate Officer/Principal 55 27/11/2014
Director TitleAgeSince
Chairman 62 03/04/2012
Director/Board Member 55 11/06/2012
Director/Board Member 56 01/06/2015
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+1.42%+16.50%+323.08%+390.57% 8.48B
+3.75%+1.08%-18.25%-15.37% 76.73B
-2.36%+0.23%-49.27%-9.64% 60.29B
-1.06%+3.10%+25.27%+24.97% 53.68B
-1.07%+0.35%+18.67%+104.43% 38.31B
-3.72%-4.75%-42.20%-40.98% 19.5B
+4.76%+4.06%+111.06%+123.12% 17.86B
+5.39%+12.47%+72.11%+768.52% 17.21B
-0.04%-.--%+68.78%+135.69% 14.02B
-2.33%+1.09%+6.47%-14.53% 13.55B
Average +0.48%+3.52%+51.57%+146.68% 31.96B
Weighted average by Cap. +0.42%+2.40%+12.18%+72.66%
See all sector performances

Financials

2025 *2026 *
Net sales 15.04B 16.46B 2.1B 1.81B 1.68B 1.57B 2.88B 180B 3.22B 20.36B 7.7B 84.32B 7.86B 7.7B 312B 11.65B 12.75B 1.62B 1.4B 1.3B 1.21B 2.23B 140B 2.49B 15.77B 5.96B 65.32B 6.09B 5.96B 242B
Net income 5.68B 6.22B 792M 682M 635M 591M 1.09B 68.12B 1.22B 7.69B 2.91B 31.87B 2.97B 2.91B 118B 2.94B 3.22B 410M 353M 328M 306M 562M 35.23B 629M 3.98B 1.5B 16.48B 1.54B 1.5B 61B
Net Debt -1.65B -1.81B -231M -199M -185M -172M -317M -19.84B -354M -2.24B -847M -9.28B -865M -847M -34.34B -3.22B -3.52B -448M -386M -359M -335M -615M -38.56B -688M -4.35B -1.65B -18.04B -1.68B -1.65B -66.77B
More financial data * Estimated data
Logo 3SBio Inc.
3SBio Inc is an investment holding company mainly engaged in the development, production, marketing and sale of pharmaceutical products. The Company’s core products include several biopharmaceutical drugs, TPIAO, recombinant human erythropoietin(rhEPO) products, with brand of EPIAO and SEPO, Yisaipu, Cipterbin and a small molecule drug, Mandi and tumor necrosis factor (TNF). Through its subsidiaries, the Company is engaged in project management and consultation. The Company still engages in developing innovative biological products, including mAbs, bi-specific antibodies and fusion proteins, and a number of small molecule drugs, both innovative and generic, in the areas of nephrology, oncology, auto-immune and inflammatory diseases, ophthalmology and dermatological diseases. The Company distributes its products within the domestic market and to overseas markets.
Employees
5,577
More about the company
Date Price Change Volume
15/07/25 28.60 $ +1.42% 39,234,226
14/07/25 28.20 $ +12.13% 67,645,990
11/07/25 25.15 $ +3.07% 35,833,280
10/07/25 24.40 $ -1.61% 23,065,290
09/07/25 24.80 $ +1.02% 37,097,500

Delayed Quote Hong Kong S.E., July 15, 2025 at 04:08 pm

More quotes
Trading Rating
Investor Rating
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
26.14CNY
Average target price
20.00CNY
Spread / Average Target
-23.47%
Consensus

Quarterly revenue - Rate of surprise